Nu.Q®
Discover the risk for certain canine cancers in-house, instantly.
Nu.Q® on the Element i+ analyzer is exclusively available from Antech as an in-house test option.
Nu.Q® on the Element i+ is the industry’s only in-house canine cancer blood test, offered exclusively by Antech.
Nu.Q® uses breakthrough technology to screen for some of the most prevalent types of canine cancers, especially lymphoma and hemangiosarcoma*.
Accurate and convenient in-house cancer blood test
Only requires 50μL of EDTA plasma from a patient with high (>70%) detection rates for lymphoma and hemangiosarcoma — all at an affordable cost for pet owners.
Innovative cancer assessment
Measures canine plasma nucleosome concentration and helps determine current likelihood of certain cancers.
Affordable testing and immediate results
Refine your differential list, helping you inform pet owners of risk level for common cancer types.
Seamless integration into routine senior wellness assessments
The efficient workflow for Nu.Q® on the Element i+ analyzer makes it easy to add to routine wellness diagnostics for your patients that are at high risk for cancer.
*Nu.Q® is not a confirmatory test for cancer. Nu.Q results should act as an impetus to perform additional diagnostics to obtain a diagnosis. Elevated plasma nucleosome concentration does not tell you which cancer is present, and further diagnostics will be needed. Certain inflammatory conditions may increase plasma nucleosome concentration and in these instances Nu.Q cannot differentiate between cancer and an inflammatory response.
Accessible, Affordable, and Quantitative
1 in 4 dogs get cancer.1 With Nu.Q®, you can help determine the current likelihood of certain cancers — like lymphoma and hemangiosarcoma, with a blood test for plasma nucleosomes in dogs.
Indications:
- Older dogs (≥7 years of age)
- Younger dogs (≥4 years of age) for breeds known to be at a higher risk of developing cancer
Nu.Q®️ on the Element i+ analyzer is exclusively available from Antech as an in-house test option.
Evaluate risk of certain cancer types instantly.
Empowering veterinary care teams with the industry’s only in-house canine cancer blood test.
Cancer is a leading cause of death in older dogs, with nearly 50% over 10 years of age developing the disease. Over 6 million dogs are diagnosed² with cancer in the United States every year — often far too late. Nu.Q® on the Element i+ allows you to interpret results and develop a plan of action before your patient goes home.
You can evaluate risk of certain cancer types instantly, right at your fingertips. Simply run a Nu.Q® blood test on the in-house Element i+ Analyzer — both cost-effective and simple, requiring only 50μL of EDTA plasma from your patient. Element i+ delivers fast and accurate immunodiagnostic test results on a sleek and compact platform with an expanding test menu.
Canine Cancer | T4 | cTSH | Cortisol | Progesterone | cCRP
The Element i+ analyzer uses cutting-edge immunodiagnostics technology.
How does Nu.Q® work?
- DNA is compacted within a cell’s nucleus in the form of chromosomes.
- Nucleosomes (small, structural units comprised of DNA and a histone protein core) allow chromosomes to stack and fold into their normal conformation within each cell nucleus.
- For certain types of cancer, nucleosomes are released into the blood and can be measured using specific antibodies.
- Nucleosomes in patient plasma measured with Nu.Q® can serve as a biomarker to help identify patients who may have cancer.³
REFERENCES:
1. Cancer in Pets. American Veterinary Medical Association. (2022). Retrieved 9 July 2022, from https://www.avma.org/resources/pet-owners/petcare/cancer-pets
2. National Cancer Institute: https://ccr.cancer.gov/Comparative-Oncology-Program/pet-owners/what-is-comp-onc#:~:text=It%20has%20been%20estimated%20that,in%20cats%20made%20each%20year
3. Wilson-Robles, H., Bygott, T., Kelly, T., Miller, T., Miller, P., & Matsushita, M. et al. (2022). Evaluation of plasma nucleosome concentrations in dogs with a variety of common cancers and in healthy dogs. BMC Veterinary Research, 18(1). https://doi.org/10.1186/s12917-022-03429-8
PEER-REVIEWED STUDIES
Lymphoma paper: https://pubmed.ncbi.nlm.nih.gov/34399763/
Hemangiosarcoma paper: https://pubmed.ncbi.nlm.nih.gov/34187493/
2020 cancer vs healthy dogs: https://pubmed.ncbi.nlm.nih.gov/32866177/
Nu.Q® in Practice
Tune in to an episode of Antech’s Tails from the Lab podcast to hear how Nu.Q® was used to whittle down a differential list in a real-life hypercalcemia case.
Download Resources
Nu.Q® FAQ
Have questions about Nu.Q®? Fill out this form and an Antech representative will reach out to you.
